AAPG Stock Forecast & Price Target

Ascentage Pharma Group is supported by two de-risked commercial anchors, olverembatinib and lisaftoclax, which already have approvals in China and are being advanced through registrational global studies in hematologic malignancies. Its positive outlook is reinforced by differentiated clinical profiles: lisaftoclax shows a faster five-day ramp, lower drug-drug interaction burden, and strong response data, while olverembatinib has extensive real-world experience, activity against resistant mutations like T315I, and a broad opportunity in refractory CML and Ph+ ALL. With about $279M in cash at 2Q26, expected FY26 revenues of $94.5M, and runway into 2028, the company has time to reach major catalysts, including multiple 2027 readouts and potential NDA filings.

Ascentage Pharma Group is viewed negatively because its core blood-cancer pipeline faces major efficacy and commercialization risk: venetoclax’s failure to improve overall survival in the registrational Phase 3 VERONA study raises doubt that stronger response rates will convert into durable benefit, while GLORA-4 may miss or underdeliver on overall survival despite possible accelerated approval. Lisaftoclax and sonrotoclax both show meaningful hematologic toxicity, with high rates of grade ≥3 neutropenia, infections, dose reductions, interruptions, and even treatment-emergent deaths, which could constrain dose intensity, physician adoption, and pricing power versus generic hypomethylating agents. APG-3288 also enters a crowded BTK degrader field with a high bar set by Nurix’s bexobrutideg and BeOne Medicines’ BGB-16673, so any lack of safety or clear differentiation in heavily pretreated, BTKi-resistant patients would weaken its commercial potential.